Vanguard Fiduciary Trust
MLYS icon

Vanguard Fiduciary Trust’s Mineralys Therapeutics MLYS Stock Holding History

Vanguard Fiduciary Trust’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.2M Buy
450,370
+75,108
+20% +$2.06M ﹤0.01% 1706
2026
Q1 		$10.2M Buy
+375,262
New +$11M ﹤0.01% 1701

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Fiduciary Trust's MLYS Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Mineralys Therapeutics (MLYS) stake by 20% in Q2 2026, buying an estimated $2.06M and bringing the position to 450,370 shares worth $12.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1706.

Vanguard Fiduciary Trust first reported a position in MLYS in Q1 2026 and has held it in 2 quarters since. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Vanguard Fiduciary Trust held 450,370 shares of Mineralys Therapeutics worth $12.2M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 75,108 Mineralys Therapeutics shares in Q2 2026, an estimated $2.06M.
  • Mineralys Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #1706 holding.
  • Vanguard Fiduciary Trust first reported a position in Mineralys Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.